Chengyin Min is the Head of Immunology at Tango Therapeutics and brings significant experience in immuno-oncology, target discovery, and in vivo biology. She joined Tango Therapeutics in 2017, after serving as a consultant at Third Rock Ventures, where she helped to build the scientific functions at Tango. Prior to Tango, Chengyin was the leukemia program lead at Acetylon Pharmaceuticals, which was acquired by Celgene.
Chengyin obtained her Bachelor of Science in biotechnology from Shanghai JiaoTong University and her doctorate in biochemistry and cancer biology from Boston University School of Medicine. She completed her postdoctoral training at Dana-Farber Cancer Institute.